Lilly’s Lechleiter to chairman
Executive SummaryLilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005
You may also be interested in...
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.